Navigation
banner

Biomarker Summit

2018-01-232018-02-132017-11-27
EARLY BIRD DISCOUNT! Register by Feb 13, 2018 to receive 10% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


ssclaas=mixsessionprlval=1Array ( [7854] => 1 )
Day 1 - Tuesday, March 27, 2018
7:30
Continental Breakfast & Registration
ssclaas=mixsessionprlval=1Array ( [7854] => 1 )
ssclaas=mixsessionprlval=1Array ( [7854] => 1 )
ssclaas=mixsessionprlval=1Array ( [7854] => 1 )
10:00
Morning Networking Break
ssclaas=parallelprlval=1Array ( [7859] => 1 [7854] => 1 )
Oncology Biomarkers
Immuno-oncology Biomarkers

10:45
 
Sandip  Patel
Sandip Patel
Assistant Professor, Cancer Immunotherapy Program
University of California, San Diego
About Speaker: Sandip Patel, MD. Assistant Professor, Medical Oncology/Hematology, UC San Diego Moores Cancer Center Dr. Sandip Patel, MD is a medical oncologist focused on early development of novel immunotherapy, in particular early phase clinical trials of ... Read Full Bio 
 
 
Sandip  Patel
Sandip Patel
Assistant Professor, Cancer Immunotherapy Program
University of California, San Diego
 
About Speaker:

Sandip Patel, MD. Assistant Professor, Medical Oncology/Hematology, UC San Diego Moores Cancer Center

Dr. Sandip Patel, MD is a medical oncologist focused on early development of novel immunotherapy, in particular early phase clinical trials of cancer immunotherapy and thoracic oncology immunotherapy trials. His research focus is on predictive biomarkers for immunotherapeutic response and generation of personalized cancer immunotherapy regimens.

He is Assistant Director of the Clinical Trials Office at UCSD Moores Cancer Center and a member of the Cancer Immunotherapy, Experimental Therapeutics (Phase 1), and Thoracic Oncology Programs. Dr. Patel earned his medical degree at Baylor College of Medicine, while performing research at MD Anderson Cancer Center. He completed a residency in Internal Medicine at UCLA Medical Center. He completed a fellowship in Medical Oncology and Hematology at Duke University Medical Center. He is triple board-certified in internal medicine, medical oncology, and hematology.

Cardiovascular Biomarkers
Biomarkers for Heart Failure & Acute Coronary Syndrome

10:45
 
Pei Pei Ping
Pei Pei Ping
Director, NIH BD2K Center of Excellence at UCLA; Professor, Medicine/Cardiology, and Bioinformatics
UCLA
About Speaker: ... Read Full Bio 
 
 
Pei Pei Ping
Pei Pei Ping
Director, NIH BD2K Center of Excellence at UCLA; Professor, Medicine/Cardiology, and Bioinformatics
UCLA
 
About Speaker:
ssclaas=parallelprlval=1Array ( [7859] => 1 [7854] => 1 )
11:10
 
Jaffer Ajani
Jaffer Ajani
Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
About Speaker: ... Read Full Bio 
 
 
Jaffer Ajani
Jaffer Ajani
Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
 
About Speaker:
11:10
 
Jim Turk
Jim Turk
Pathologist Director
Amgen
About Speaker: ... Read Full Bio 
 
 
Jim Turk
Jim Turk
Pathologist Director
Amgen
 
About Speaker:
ssclaas=parallelprlval=1Array ( [7859] => 1 [7854] => 1 )
11:35
BiTE® in hematologic malignancies: lessons learned from BLINCYTO® and moving forward
 
Cedric Dos Santos
Cedric Dos Santos
Sr Scientist | Heme/Onc Clinical Biomarkers
Amgen
About Speaker: ... Read Full Bio 
 
 
Cedric Dos Santos
Cedric Dos Santos
Sr Scientist | Heme/Onc Clinical Biomarkers
Amgen
 
About Speaker:
11:35
 
John Nolan
John Nolan

Cellarcus Technologies, LLC
About Speaker: ... Read Full Bio 
 
 
John Nolan
John Nolan

Cellarcus Technologies, LLC
 
About Speaker:
ssclaas=parallelprlval=1Array ( [7859] => 1 [7854] => 1 )
12:00
High Definition Multiplexing for Biomarker Strategies
 
Louis Levy
Louis Levy
Director Corporate & Business Development
Ultivue
About Speaker: Louis Levy began his life science career with Cepton, a strategy consulting boutique for French mid-size biotechs. As a Harvard Blavatnik Fellow, he worked on the commercialization of the Harvard technology conducive to the launch of Ultivue in 2015... Read Full Bio 
 
 
Louis Levy
Louis Levy
Director Corporate & Business Development
Ultivue
 
About Speaker:

Louis Levy began his life science career with Cepton, a strategy consulting boutique for French mid-size biotechs.

As a Harvard Blavatnik Fellow, he worked on the commercialization of the Harvard technology conducive to the launch of Ultivue in 2015. Since then, he has spearheaded corporate and business development functions.

He is a graduate from the French grande école Telecom Bretagne, with a master’s degree in engineering and from Harvard Business School, with an MBA.

 
Abstract: Biomarker discovery in immuno-oncolog...Read More 

Biomarker discovery in immuno-oncology requires the analysis of multiple protein markers (n>4) with their spatial relationships at an amenable throughput.

The scrutiny of the tumor micro-environment demands whole-slide multiplexed images featuring immune and tumor cells.

Ultivue’s InSituPlex platform fulfills this need with the data reproducibility relevant to CDx.

 Read Less
12:00
 
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
ssclaas=mixsessionprlval=1Array ( [7854] => 1 )
12:25
Lunch
ssclaas=parallelprlval=1Array ( [7859] => 1 [7854] => 1 )
Oncology Biomarkers
Circulating Tumor Cells, Microvesicles, DNA and RNA

1:55
 
Tony Pircher
Tony Pircher
Director of Immunochemistry
Biocept
About Speaker: Dr. Pircher joined the R&D department at Biocept Inc. in February 2001 and is currently leading the identification and validation of tumor specific markers for the enrichment and detection of rare circulating tumor cells (CTC) and development of ... Read Full Bio 
 
 
Tony Pircher
Tony Pircher
Director of Immunochemistry
Biocept
 
About Speaker:

Dr. Pircher joined the R&D department at Biocept Inc. in February 2001 and is currently leading the identification and validation of tumor specific markers for the enrichment and detection of rare circulating tumor cells (CTC) and development of predictive and/or prognostic CTC assays. He has extensive experience in developing proteomic and genomic diagnostic assays and is the inventor on several Biocept patents.

He received his Ph.D. in molecular endocrinology from the Karolinska Institute, Stockholm, mentored by Dr. Lars-Arne Haldosen and the world renowned steroid receptor scientist Dr. Jan-Ake Gustafsson. During his postdoctoral training he worked in the field of molecular hematology at the Pennsylvania State University in the highly prolific research lab of Dr. Don M Wojchowski, where he gained extensive experience in the enrichment of erythroid progenitor cells from blood, bone marrow and spleen. He acquired expertise in protein alteration, expression, detection and purification technologies, antibody production and cellular reporter systems.

Cardiovascular Biomarkers
Biomarkers for Metabolic Syndrome & Cardiovascular Risk

1:55
 
Szilard Voros
Szilard Voros
Founder & Chief Executive Officer
Global Genomics Group
About Speaker: Dr. Szilard Voros, MD, FACC, FSCCT, FAHA is a cardiologist, geneticist and entrepreneur. He is Founder and CEO of Global Genomics Group (“G3”), a precision-medicine-based biotechnology company, developing and commercializing diagnostic biomarkers... Read Full Bio 
 
 
Szilard Voros
Szilard Voros
Founder & Chief Executive Officer
Global Genomics Group
 
About Speaker:

Dr. Szilard Voros, MD, FACC, FSCCT, FAHA is a cardiologist, geneticist and entrepreneur. He is Founder and CEO of Global Genomics Group (“G3”), a precision-medicine-based biotechnology company, developing and commercializing diagnostic biomarkers and novel drug targets for common diseases. G3’s platform is based on the largest-ever program using DNA and RNA sequencing, proteomics, metabolomics, lipidomics and other platforms. G3 has developed a diagnostic blood test for cardiovascular disease and has identified several novel drug targets. Before G3, Voros was Chief Scientific Officer, Chief of Cardiovascular Prevention and Medical Director of Cardiovascular Imaging at Piedmont Heart Institute. He has published extensively in major scientific journals including Nature Reviews, New England Journal of Medicine, Annals of Internal Medicine, Journal of the American College of Cardiology and Circulation: Cardiovascular Genetics, etc.

ssclaas=parallelprlval=1Array ( [7859] => 1 [7854] => 1 )
2:20
 
Michael Heller
Michael Heller
Professor
University of California, San Diego
About Speaker: Michael J. Heller received his Ph.D. in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. Dr. Heller was supervisor of the DNA Technology Group at Amoco Corporation (S... Read Full Bio 
 
 
Michael Heller
Michael Heller
Professor
University of California, San Diego
 
About Speaker:

Michael J. Heller received his Ph.D. in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. Dr. Heller was supervisor of the DNA Technology Group at Amoco Corporation (Standard Oil Indiana) from 1976 to 1984. During that time, he carried out very early bioengineering and recombinant DNA work on plants, algae and photosynthetic bacteria for energy and chemical production. He also development the first fluorescent resonant energy transfer (FRET) and chemiluminescent DNA oligonucleotide probes. Additionally, he oversaw the company sponsored research work at Cetus Corporation on their related recombinant DNA efforts for energy and chemical production, which included the cloning of thermophilic enzymes. Dr. Heller was the Director of Molecular Biology at Molecular Biosystems, Inc., from 1984 to 1987.  He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer from 1987 to 1989.  He was a co-found of Nanotronics and Nanogen, and served as the Chief Technical Officer from 1993 to 2001. Nanogen carried out the successful development and commercialization of electronic DNA microarray technology for molecular diagnostic genotyping applications. Dr. Heller is now a Professor in the Departments of Nanoengineering and Bioengineering at the University California San Diego. He has also recently co-founded a new company called Biological Dynamics which will be developing new sample to answer cancer diagnostic technology, which is based on novel dielectrophoretic (DEP) microarray technology developed in his lab. Dr. Heller has extensive industrial experience in biotechnology, biomedical and molecular diagnostic devices and nanotechnology; with particular expertise in the areas of DNA probe diagnostics, DC electrophoretic and AC dielectrophoretic devices, DNA synthesis, FRET/fluorescent-based detection technologies and electric field assisted self-assembly of DNA nanocomponents. Dr. Heller has a respectable publication record, and has been an invited speaker to many scientific conferences and meetings related clinical/molecular diagnostics, DNA microarrays, biosensors, lab-on-a-chip devices, bio-MEMS and nanotechnology. He has over 50 issued US patents related to microelectronic chips, microarrays and integrated devices for DNA hybridization, miniaturized sample to answer diagnostic devices, biosensors, genomics, proteomics, nanotechnology and nanofabrication, nano-based DNA optical storage and for fluorescent energy transfer in DNA nanostructures. Dr. Heller has been a panel member for the White House (OSTP) National Nanotechnology Initiative 1999/2000; the NAS (NAE) Review of National Nanotechnology Initiative 2001-2002; the NAS(NAE) – Engineer for the 2020 - 2001/2002; and has also been involved in a number of NSF Nanotechnology Workshops.

2:20
 
J. Brent  Muhlestein
J. Brent Muhlestein
Co-Director of Cardiology Research, Intermountain Medical Center and Professor of Medicine, University of Utah
University of Utah
About Speaker: ... Read Full Bio 
 
 
J. Brent  Muhlestein
J. Brent Muhlestein
Co-Director of Cardiology Research, Intermountain Medical Center and Professor of Medicine, University of Utah
University of Utah
 
About Speaker:
ssclaas=parallelprlval=1Array ( [7859] => 1 [7854] => 1 )
2:45
 
David  Fabrizio
David Fabrizio
Leader Immunotherapy
Foundation Medicine
About Speaker: David Fabrizio has over 12 years of experience in the drug and biomarker discovery industry, and most recently in the application of next generation sequencing technologies to discover methods for cancer immunotherapy response. David's career began a... Read Full Bio 
 
 
David  Fabrizio
David Fabrizio
Leader Immunotherapy
Foundation Medicine
 
About Speaker:

David Fabrizio has over 12 years of experience in the drug and biomarker discovery industry, and most recently in the application of next generation sequencing technologies to discover methods for cancer immunotherapy response. David's career began at Adnexus Therapeutics in 2004, where he co-lead the PD1/PDL1 pre-clinical drug discovery program, leading to an acquisition by Bristol Myers Squibb in 2007. While there, his work was awarded several issued patents, including for those describing novel PD-L1, EGFR and IGFR targeting therapeutics, as well as a method for improved drug pharmacokinetics. Additionally, David also invented a novel drug selection technology, ASCENT, to rapidly identify protein based therapeutic binders using a reconstituted mRNA/protein fusion system. In 2013, David joined the startup, AbVitro, and focused on developing an immune cell next-generation sequencing/antigen target identification platform, which was subsequently acquired by Juno Therapeutics. David joined Foundation medicine in 2015, and currently leads the Cancer Immunotherapy group, which is focused on utilizing next-generation sequencing to build methods to identify responders to cancer immunotherapies.

2:45
 
 
TBA (To Be Announced)
TBA (To Be Announced)

 
About Speaker:
ssclaas=parallelprlval=1Array ( [7859] => 1 [7854] => 1 )
3:10
A workflow to evaluate PD-L1 protein expression on Circulating Tumor Cells (CTCs) from Non-Small Cell Lung Cancer (NSCLC)
 
Elodie Sollier
Elodie Sollier
Chief Scientific Officer
Vortex Biosciences
About Speaker: Elodie is Co-Founder, Chief Scientific Officer and Vice-President Research & Development for Vortex Biosciences, heading the initiatives for the commercialization of microfluidic devices for cancer research and diagnostics. Elodie received a Phys... Read Full Bio 
 
 
Elodie Sollier
Elodie Sollier
Chief Scientific Officer
Vortex Biosciences
 
About Speaker:

Elodie is Co-Founder, Chief Scientific Officer and Vice-President Research & Development for Vortex Biosciences, heading the initiatives for the commercialization of microfluidic devices for cancer research and diagnostics. Elodie received a Physics Engineering Degree from Grenoble Institute of Technology and a PhD in Physics for Life Science from CEA LETI Minatec at Grenoble, France. Her PhD was followed by post-doctoral research in Bioengineering Department, University of California, Los Angeles, with Professor Dino Di Carlo. Her work resulted in the publication of articles in peer-reviewed journals, review papers, presentations in international conferences, and several patents including technologies licensed to Vortex Biosciences from UCLA.

Elodie’s expertise includes the development of new microfluidic devices for biological applications, focusing especially on blood sample preparation and analysis. She has been investigating different microfabrication approaches for transitioning from laboratory research to commercialization.

 
Abstract: Many tumors evade immune surveillance...Read More 

Many tumors evade immune surveillance by deploying immunosuppressive mechanisms and co-opting immune checkpoint pathways, such as PD-1/PD-L1. PD-1/PD-L1 pathway blockade is a highly promising therapy with durable antitumor responses in a variety of cancers. Challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Evaluation of PD-L1 expression is generally regarded as an inclusion criterion for clinical trials. Current methods rely on the analysis of biopsies, which are invasive and carry medical risks. Analysis of CTCs is a noninvasive alternative that may provide more representative information on the tumor(s) in real-time, and allow the monitoring of treatment effectiveness. Here, we present an integrated workflow for the analysis of PD-L1 protein expression on CTCs isolated from metastatic NSCLC patients with the Vortex Biosciences VTX-1 liquid biopsy system.

Cell lines expressing various level of PD-L1 and white blood cells from healthy donors were used to optimize the PD-L1 immunostaining assay. Several PD-L1 antibodies were titrated, and their specificity estimated with isotype controls. PD-L1 expression quantification was evaluated using two independent methods. Clinical validation was performed on blood samples collected from a cohort of NSCLC patients (stage IV) with known PD-L1 tumor status. CTCs were isolated using the VTX-1 System, immunostained, classified, and their PD-L1 expression quantified.

We have developed a PD-L1 immunofluorescent assay that shows specificity, sensitivity, and very good intra-assay repeatability. This assay was validated on CTCs isolated from a small cohort of metastatic NSCLC patients. Preliminary data shows heterogeneity in PD-L1 expression levels across CTCs from the same patient. Interestingly, among PD-L1+ CTCs, both traditional CK+/PD-L1+ and CK-/PD-L1+ cells were observed. To move toward a more automated workflow for immunostaining, imaging, and fluorescence signal analysis, methods to collect CTCs on glass slides were evaluated, with cell recovery ranging from 33 to 98%.

We demonstrated the feasibility of evaluating PD-L1 protein expression on CTCs isolated with the VTX-1. While further clinical validation is warranted, this test could represent a simple non-invasive method to help identify patients likely to respond to PD-1/PD-L1 immunotherapies. Future work will focus on compatibility of the assay with automated staining, imaging and analysis platforms.

 Read Less
3:10
 
Rhonda Rhyne
Rhonda Rhyne
Chief Executive Officer
Prevencio
About Speaker: Rhonda Rhyne has more than 25 years of executive medical technology research and commercialization experience and is currently CEO, Chief Translational Medicine Officer and Board Director for Prevencio, Inc., a Seattle-based company developing multi-... Read Full Bio 
 
 
Rhonda Rhyne
Rhonda Rhyne
Chief Executive Officer
Prevencio
 
About Speaker:

Rhonda Rhyne has more than 25 years of executive medical technology research and commercialization experience and is currently CEO, Chief Translational Medicine Officer and Board Director for Prevencio, Inc., a Seattle-based company developing multi-protein blood tests for obstructive heart disease; 1-year risk for myocardial infarct, stroke, and CV death; obstructive peripheral artery disease…and more. She also serves as Board Director for Aminex Therapeutics and OtoNexus Medical Technologies, both Seattle-area companies. As a medical technology industry leader, Rhonda has received multiple awards, including Ernst & Young's Entrepreneur of the Year--Medical Products, San Diego; Deloitte's Fast 50 for 50 Fastest Growing Technology and Life Science Companies in Southern California; San Diego's Business Journal's Women Who Mean Business; and Athena's Pinnacle Individual in BioSciences. Rhonda also authored the women’s leadership book, Keys to the Corner Office: Success Strategies for Women by Women (www.keytothecorneroffice.com). A portion of net proceeds is donated to OUR Rescue, a nonprofit dedicated to fighting sex trafficking. Rhonda received her Bachelor of Pharmacy from Washington State University and MBA from University of California, Los Angeles (UCLA). @rhondarhyne, www.linkedin.com/in/rhondarhyne, www.prevenciomed.com

ssclaas=mixsessionprlval=1Array ( [7854] => 1 )
3:35
Afternoon Networking Break
ssclaas=parallelprlval=0Array ( [7859] => 3 )
Round Table Topics

Array ( [7884] => Array ( [sheduleid] => 7884 [new_session] => 1 [single_conf] => 0 [cfid] => 7859 [schedule_type] => speakerslot [prev] => 1522164900 [next] => 1522172100 )[7885] => Array ( [sheduleid] => 7885 [new_session] => 0 [single_conf] => 0 [cfid] => 7859 [schedule_type] => speakerslot [prev] => 1522164900 [next] => 1522172100 )[7890] => Array ( [sheduleid] => 7890 [new_session] => 0 [single_conf] => 0 [cfid] => 7859 [schedule_type] => speakerslot [prev] => 1522164900 [next] => 1522172100 ))
4:20
Round Table Session1
Cristina Stefan
Cristina Stefan
Global Clinical Leader, Oncology Diagnostics
Roche
 
Cristina Stefan
Cristina Stefan
Global Clinical Leader, Oncology Diagnostics
Roche
 
About Speaker:

Experienced, innovative oncologist with clinical and academic background, also with industry experience I had founded a number of institutes including the African Cancer Institute at Stellenbosch University in Cape Town, the African Medical Research and Innovation Institute, the African Pediatric and Adolescent Group and had the original initiatives such as the first successful twinning between 2 oncology units in Africa and the formation of the health economics group.

From head of an academic unit of pediatric hematology oncology to vice president of the Medical Research Council in South Africa and first woman president  of African Organization for Research and Training in Cancer (Aortic) I held a number of successful management and leadership positions. Strategic expertise across the entire oncology spectrum, from diagnostics to pharma, from innovation to effective management and leadership with in depth knowledge and experience of low and mid income countries, I have been working in more than 25 African countries. 

Author and coauthor of 3 oncology books, member of Academy of Science and Fellow of the Royal Society of Science in South Africa and Romania, I was voted in 2016 the most influential African woman in business and government.

Round Table Session2: Overcoming Commercialization Challenges in Biomarker Development (Chairperson: John Schilling & Gary Gustavsen)
John Schilling
John Schilling
Director & Advisor of Diagnostics
Eli Lilly
 
John Schilling
John Schilling
Director & Advisor of Diagnostics
Eli Lilly
 
About Speaker:

John Schilling, MBA, is a seventeen-year employee of Eli Lilly & Co., who currently is Director – Advisor of Diagnostics for the Personalized Medicine - Tailored Therapeutics Division within Lilly Research Laboratories.   John is responsible for executing the global diagnostic personalized medicine strategy to enable the capabilities to deliver for the global drug teams across Lilly’s pharmaceutical business units.  John’s prior responsibilities at Lilly have been as Global Marketing Director for the global Forteo and Evista brands.

Prior to Eli Lilly, John has worked as Marketing Director for Bausch & Lomb’s pharmaceutical division representing the anti-allergy and dry eye products.  He also was U.S. Brand Manager for AstraZeneca’s Prilosec brand.  Prior to John’s pharmaceutical experience, he worked in the diagnostic industry for Abbott Laboratories Diagnostics Division, Sanofi Diagnostics Pasteur, Bayer Diagnostics and Centocor in different sales, sales management, global marketing and business development roles. 

Gary  Gustavsen
Gary Gustavsen
Vice President
Health Advances
 
Gary  Gustavsen
Gary Gustavsen
Vice President
Health Advances
 
About Speaker:

Gary Gustavsen joined Health Advances in 2005 and leads its Personalized Medicine Practice. A noted writer and workshop leader in the field of companion diagnostics and personalized medicine, his work focuses on commercialization strategy, indication prioritization, pricing and reimbursement strategy, system economics, and business development opportunities for both diagnostic and therapeutic clients.
Prior to joining Health Advances, Gary was a researcher at Brookhaven National Lab evaluating a proprietary line of synthetic growth factors. Gary also worked in the Cell & Tissue Technologies group at Becton Dickinson, the Exploratory Cancer Research group at OSI Pharmaceuticals, and most recently the Corporate Strategy group at Millennium Pharmaceuticals. Gary received his Bachelors degree in Biomedical Engineering from Duke University and his Masters degree in Biomedical Engineering from Stony Brook University.

 

 

ssclaas=mixsessionprlval=1Array ( [7854] => 1 )
5:35
Networking Reception & Poster Session
ssclaas=mixsessionprlval=1Array ( [7858] => 1 )
Day - 2 Wednesday, March 28, 2018
 
7:15
Breakfast with Mentors from Academia & Industry
ssclaas=parallelprlval=1Array ( [7855] => 1 [7858] => 1 )
Inflammatory & Immunological Biomarkers
Biomarkers of Early Progressive Inflammatory & Immunological Diseases

8:30
Biomarkers and Personalized Medicine in Rheumatoid Arthritis and Inflammatory Bowel Disease
 
Mark Curran
Mark Curran
Vice President, Immunology, Systems Pharmacology & Biomarkers
Janssen
About Speaker: ... Read Full Bio 
 
 
Mark Curran
Mark Curran
Vice President, Immunology, Systems Pharmacology & Biomarkers
Janssen
 
About Speaker:
Neurological Biomarkers
Biomarkers for Early Identification of Neurological Disease

8:30
 
Richard  Batrla-Utermann
Richard Batrla-Utermann
Medical Director
Roche
About Speaker: ... Read Full Bio 
 
 
Richard  Batrla-Utermann
Richard Batrla-Utermann
Medical Director
Roche
 
About Speaker:
ssclaas=parallelprlval=1Array ( [7855] => 1 [7858] => 1 )
8:55
 
Toshiaki  Kawakami
Toshiaki Kawakami
Professor, Division of Cellular Biology
La Jolla Institute for Immunology & Allergy
About Speaker: 1978 MD, 1983 PhD from The University of Tokyo 1984-88 Postdoc at the NCI/NIH 1990 Assistant Professor, La Jolla Institute for Allergy and Immunology (LJI) 2000 Professor, LJI... Read Full Bio 
 
 
Toshiaki  Kawakami
Toshiaki Kawakami
Professor, Division of Cellular Biology
La Jolla Institute for Immunology & Allergy
 
About Speaker:

1978 MD, 1983 PhD from The University of Tokyo
1984-88 Postdoc at the NCI/NIH
1990 Assistant Professor, La Jolla Institute for Allergy and Immunology (LJI)
2000 Professor, LJI

8:55
 
Arti  Gaur
Arti Gaur
Assistant Professor of Neurology
Dartmouth Geisel School of Medicine
About Speaker: Dr. Gaur is an Assistant Professor of Neurology and Member of the Norris Cotton Cancer Center at the Geisel School of Medicine, Dartmouth. She received her BS from Rochester Institute of Technology, NY; an MS from University of Rochester, NY and her ... Read Full Bio 
 
 
Arti  Gaur
Arti Gaur
Assistant Professor of Neurology
Dartmouth Geisel School of Medicine
 
About Speaker:

Dr. Gaur is an Assistant Professor of Neurology and Member of the Norris Cotton Cancer Center at the Geisel School of Medicine, Dartmouth. She received her BS from Rochester Institute of Technology, NY; an MS from University of Rochester, NY and her PhD from University of Cologne, Germany.

At Dartmouth, her group studies the molecular basis of neurological pathologies, specifically gliomas. Dr. Gaur is the Study Chair on an Alliance funded, multi-institutional, prospective clinical trial that is establishing a comprehensive panel of diagnostic and prognostic markers as well as biomarkers of tumor burden, treatment efficacy and toxicity. Furthermore in this trial her group is testing patient tumors ex vivo and establishing novel therapies to treat gliomas.  The other sites for this trial are University of Vermont Medical Center, Tufts Medical Center and Massachussets General Hospital.  Additionally, Dr. Gaur’s group is also developing innovative, in vivo wireless, nano scale devices, to measure multiple biomarkers of health that can predict and track the course of diseases, enable real-time evaluation of treatment efficacy and deliver targeted therapies in patients suffering from incurable and debilitating neurological disorders.

ssclaas=parallelprlval=1Array ( [7855] => 1 [7858] => 1 )
9:20
 
Pierluigi Mauri
Pierluigi Mauri
Chief of Proteomics & Metabolomics
Proteomics and Metabolomics Laboratory - CNR, Institute for Biomedical Tecnologies (ITB-CNR)
About Speaker: Pierluigi Mauri is chief of Proteomics and Metabolomics Labat ITB-CNR. He has a notable experience in the development and application of several technologies (HPLC, capillary electrophoresis, mass spectrometry) for the identification and quantificati... Read Full Bio 
 
 
Pierluigi Mauri
Pierluigi Mauri
Chief of Proteomics & Metabolomics
Proteomics and Metabolomics Laboratory - CNR, Institute for Biomedical Tecnologies (ITB-CNR)
 
About Speaker:

Pierluigi Mauri is chief of Proteomics and Metabolomics Labat ITB-CNR. He has a notable experience in the development and application of several technologies (HPLC, capillary electrophoresis, mass spectrometry) for the identification and quantification of several biomolecules in complex matrices. He has been involved in the study of the bioavailabily of several drugs in humans and animals.
He has set-up a proteomics laboratory based on the MudPIT (Multidimensional Protein Identification Technology), a gel-free approch (using two dimensional chromatography coupled to tandem mass spectrometry, 2DC-MS/MS) and a parallel computing system for proteomics. This instrumentation allows for the proteomic profiling of biological samples, without limitations, according to to protein molecular weight, pI or hydrophobicity and guarantees high productivity. Using this methodology, secreted proteins from tumor (FASEB 2005) and immune system cells (JEM, 2011, Immunity, 2016) have been characterized.
Furthermore, direct analysis of biological samples (JMS 2007), enzymatic complexes (Biochimie 2006), development of novel methodological approaches for studying switchredox proteins (JBC 2005 and 2006, JMB 2006), degenerative diseases (Blood, 2012) and structural and functional characterization of proteins (Biol. Chem. 2004, FEBS 2006) have been performed. His main investigations concern molecular profiles obtained by MS-based methodologies and focused on clinical applications (J Proteome Research,
2014; JACC 2013; Nature Commun, 2014; Cardiovasc Res. 2011; Biol Reprod. 2013), including computational methods (J Clin Bioinforma. 2013; Methods Enzymology, 2008) He is co-author of more than 150 scientific publications, he has participated in numerous international congresses and has taught in several metabolomics and proteomics courses.

9:20
 
Douglas Scharre
Douglas Scharre
Professor of Clinical Neurology and Psychiatry, Center for Cognitive and Memory Disorders, Center for Neuromodulation
Ohio State University, Wexner Medical Centre
About Speaker: ... Read Full Bio 
 
 
Douglas Scharre
Douglas Scharre
Professor of Clinical Neurology and Psychiatry, Center for Cognitive and Memory Disorders, Center for Neuromodulation
Ohio State University, Wexner Medical Centre
 
About Speaker:
ssclaas=parallelprlval=1Array ( [7855] => 1 [7858] => 1 )
9:45
 
Andrew  Holman
Andrew Holman
Chief Executive Officer & Co-founder
Inmedix Inc and Inmedix UK Ltd
About Speaker: Andrew J. Holman, M.D., is a clinical rheumatologist, CEO and Co-founder of Inmedix, Inc. in Seattle and its subsidiary, Inmedix UK, Ltd. He established Inmedix to validate and commercialize autonomic nervous system (ANS) diagnostics and therapeutics... Read Full Bio 
 
 
Andrew  Holman
Andrew Holman
Chief Executive Officer & Co-founder
Inmedix Inc and Inmedix UK Ltd
 
About Speaker:

Andrew J. Holman, M.D., is a clinical rheumatologist, CEO and Co-founder of Inmedix, Inc. in Seattle and its subsidiary, Inmedix UK, Ltd. He established Inmedix to validate and commercialize autonomic nervous system (ANS) diagnostics and therapeutics to enhance immunosuppressive outcomes for patients with autoimmune diseases. He trained at the University of Washington (rheumatology fellowship), Presbyterian-St. Luke’s Medical Center (internal medicine residency), the University of Missouri-Columbia (M.D.) and Bowdoin College (A.B., Chemistry). Currently, he is also a Clinical Associate Professor Medicine at the University of Washington. His research identified the role of ANS assessment as a predictor of immunosuppressive treatment outcomes in patients with autoimmune diseases as well as how to enhance those outcomes through adjunctive ANS therapeutics. He discovered the role of dopamine agonists in the treatment of fibromyalgia and elucidated the dysautonomic effects of positional cervical cord compression (PC3) in humans with widespread pain.

9:45
 
Andreas Jeromin
Andreas Jeromin
Chief Medical Officer
Quanterix
About Speaker: Andreas Jeromin, PhD, has more than 25 years of experience in CNS clinical diagnostics and companion diagnostics and co-authors more than 150 publications. He is the founder of Atlantic Biomarkers, Inc., and currently the consulting Chief Medical Off... Read Full Bio 
 
 
Andreas Jeromin
Andreas Jeromin
Chief Medical Officer
Quanterix
 
About Speaker:

Andreas Jeromin, PhD, has more than 25 years of experience in CNS clinical diagnostics and companion diagnostics and co-authors more than 150 publications. He is the founder of Atlantic Biomarkers, Inc., and currently the consulting Chief Medical Officer to Quanterix Corp.

ssclaas=mixsessionprlval=1Array ( [7858] => 1 )
10:10
Morning Networking Break
ssclaas=parallelprlval=1Array ( [7855] => 1 [7858] => 1 )
Inflammatory & Immunological Biomarkers
Biomarkers as Surrogate Endpoints for Clinical Trials

10:40
 
Calixte  Monast
Calixte Monast
Senior Scientist
Janssen R&D
About Speaker: Cal received his PhD from the University of Pennsylvania where he worked on computational and experimental analysis of signal transduction. For the last five years, Cal has worked as a computational biologist in the Immunology Biomarker department at... Read Full Bio 
 
 
Calixte  Monast
Calixte Monast
Senior Scientist
Janssen R&D
 
About Speaker:

Cal received his PhD from the University of Pennsylvania where he worked on computational and experimental analysis of signal transduction. For the last five years, Cal has worked as a computational biologist in the Immunology Biomarker department at Janssen R&D with a focus on inflammatory bowel disease. Cal's projects include identifying surrogate markers for disease severity, developing strategies for patient stratification, and executing biomarker strategies in early phase clinical studies.

Neurological Biomarkers
Monitoring Progression and Treatment Efficacy using Biomarkers

10:40
 
Stephen J. Kolb
Stephen J. Kolb
Associate Professor, Department of Neurology and Biological Chemistry & Pharmacology; Director, Ohio State ALS/MND Multidisciplinary Clinic and Research Program
The Ohio State University Wexner Medical Center
About Speaker: ... Read Full Bio 
 
 
Stephen J. Kolb
Stephen J. Kolb
Associate Professor, Department of Neurology and Biological Chemistry & Pharmacology; Director, Ohio State ALS/MND Multidisciplinary Clinic and Research Program
The Ohio State University Wexner Medical Center
 
About Speaker:
ssclaas=parallelprlval=1Array ( [7855] => 1 [7858] => 1 )
11:05
 
Morten Karsdal
Morten Karsdal
Chief Executive Officer
Nordic Bioscience A/S
About Speaker: Nordic Bioscience A/S... Read Full Bio 
 
 
Morten Karsdal
Morten Karsdal
Chief Executive Officer
Nordic Bioscience A/S
 
About Speaker:

Nordic Bioscience A/S

11:05
 
Mark  Frasier
Mark Frasier
Vice President, Research Programs
Michael J. Fox Foundation
About Speaker: Dr. Frasier has been with the Michael J Fox Foundation since 2006. He earned an undergraduate degree in Biochemistry from the University of Dayton and a PhD in Pharmacology from Loyola University Chicago. He completed his postdoctoral work in the Neu... Read Full Bio 
 
 
Mark  Frasier
Mark Frasier
Vice President, Research Programs
Michael J. Fox Foundation
 
About Speaker:

Dr. Frasier has been with the Michael J Fox Foundation since 2006. He earned an undergraduate degree in Biochemistry from the University of Dayton and a PhD in Pharmacology from Loyola University Chicago. He completed his postdoctoral work in the Neuroscience Discovery Research Group at Eli Lilly, Inc., in Indianapolis, Indiana, where he worked on drug-discovery research in Parkinson's and Alzheimer's disease.

ssclaas=parallelprlval=1Array ( [7855] => 1 [7858] => 1 )
11:30
 
Xuemei Zhao
Xuemei Zhao
Principal Scientist, Translational Molecular Biomarkers
Merck
About Speaker: Xuemei Zhao obtained her Ph.D. in Chemistry at Columbia University and did her postdoctoral training at Cold Spring Harbor Laboratory.  Afterwards, Xuemei joined the Proteomics Department at Merck Research Laboratories.  Her group was responsible f... Read Full Bio 
 
 
Xuemei Zhao
Xuemei Zhao
Principal Scientist, Translational Molecular Biomarkers
Merck
 
About Speaker:

Xuemei Zhao obtained her Ph.D. in Chemistry at Columbia University and did her postdoctoral training at Cold Spring Harbor Laboratory.  Afterwards, Xuemei joined the Proteomics Department at Merck Research Laboratories.  Her group was responsible for biochemical sample preparation for LC-MS based proteomics profiling in biomarker discovery and new target identification.  Xuemei then moved on to focus on clinical biomarker development and implementation.  Currently, Xuemei leads the immunoassay group in Translational Molecular Biomarkers to support clinical programs across all disease areas at Merck.

11:30
 
Robert Rissman
Robert Rissman
Assistant Professor
University of California, San Diego
About Speaker: Novel biomarker discovery research and preclinical models of neurodegenerative disease.... Read Full Bio 
 
 
Robert Rissman
Robert Rissman
Assistant Professor
University of California, San Diego
 
About Speaker:

Novel biomarker discovery research and preclinical models of neurodegenerative disease.

ssclaas=parallelprlval=1Array ( [7855] => 1 [7858] => 1 )
11:55
Functional Relevance of Surrogate Biomarkers in Clinical Trials
 
Anuraag  Shrivastav
Anuraag Shrivastav
Associate Professor, Department of Biology
University of Winnipeg
About Speaker: Dr. Anuraag Shrivastav completed his PhD in 2002 from the Banaras Hindu University, India. He received postdoctoral fellowship from Canadian Institutes of Health Research and obtained postdoctoral training at the department of Pathology and Laborator... Read Full Bio 
 
 
Anuraag  Shrivastav
Anuraag Shrivastav
Associate Professor, Department of Biology
University of Winnipeg
 
About Speaker:

Dr. Anuraag Shrivastav completed his PhD in 2002 from the Banaras Hindu University, India. He received postdoctoral fellowship from Canadian Institutes of Health Research and obtained postdoctoral training at the department of Pathology and Laboratory Medicine and Saskatchewan Cancer Agency, University of Saskatchewan, Canada. Dr Shrivastav is a faculty member at the University of Winnipeg and adjunct member at the University of Manitoba and CancerCare Manitoba. He has published over 40 peer-reviewed articles in International journals of repute. His laboratory is engaged in studying cellular signaling mechanisms that are intricately linked to homeostasis that control cell proliferation, survival and death in cancer cells. Currently, his research group is actively pursuing scientific research to identify novel markers for CRC screening and early detection. Dr. Shrivastav is also Principal, VastCon Inc – A University of Winnipeg spinoff dedicated to developing novel biomarkers based simple prognostic/diagnostic tests.

11:55
 
Christian  Loch
Christian Loch
Chief Executive & Science Officer
AVMBioMed
About Speaker: ... Read Full Bio 
 
 
Christian  Loch
Christian Loch
Chief Executive & Science Officer
AVMBioMed
 
About Speaker:
ssclaas=mixsessionprlval=1Array ( [7858] => 1 )
12:20
Lunch Session: Big Data Analytics & Bioinformatics for Biomarkers Development
ssclaas=mixsessionprlval=1Array ( [7858] => 1 )
ssclaas=mixsessionprlval=1Array ( [7858] => 1 )
ssclaas=mixsessionprlval=1Array ( [7858] => 1 )
ssclaas=mixsessionprlval=1Array ( [7858] => 1 )
ssclaas=mixsessionprlval=1Array ( [7858] => 1 )
ssclaas=mixsessionprlval=1Array ( [7858] => 1 )
Keynote Panel
ssclaas=mixsessionprlval=1Array ( [7858] => 1 )
4:05
Conference Concludes